Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)

NCT02463305 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT02463305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02463305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)
Lead sponsor
University of Colorado, Denver
Phase
Phase 1
Overall status
Withdrawn
Start date
August 31, 2022
Completion date
March 1, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative